It took a while for the science to basically catch up to that suspicion.” In these types of “recessive” conditions, the ...

US FDA accepts Roche’s NDA for giredestrant in ESR1-mutated, ER-positive advanced breast cancer: Basel Saturday, February 21, 2026, 11:00 Hrs [IST] Roche announced that the Unit ...

The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free ...

Cullinan Therapeutics (NASDAQ:CGEM) executives highlighted multiple upcoming catalysts across the company’s oncology and autoimmune portfolio during a presentation at Citi’s Virtual Oncology ...

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

Five years ago, I finished treatment and was determined to be no evidence of disease. Until my most recent CT scan, there’s been no sign of recurrence.

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT ...

Even before a tumor in the pancreas becomes discernible, an activated cancer gene actively remodels its future environment ...

A study from an international team of experts in veterinary medicine, human medicine and genomics provides the first ...

A hidden clue may explain why some mutated cells become cancerous and others don’t: how fast they divide. A new study from researchers at Sinai Health in Toronto reveals that the total time it takes ...